Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple claims are not supported by the provided label excerpts (especially administration frequency and all discount/PAP program claims). Additionally, key safety-critical label sections (contraindications, boxed warnings, and other warnings/precautions) are not included in the provided excerpts, preventing verification of safety-label alignment.
Category Scores
Accurate Statements
Vascepa is an omega-3 fatty acid derivative.
Supported by 11 DESCRIPTION (icosapent ethyl is an ethyl ester of omega-3 fatty acid EPA).
Vascepa helps reduce triglyceride levels.
Supported by 1 INDICATIONS AND USAGE (reduces TG levels in indicated adult populations) and 12 CLINICAL PHARMACOLOGY (reduces TG vs placebo).
Vascepa is available in the form of capsules.
Supported by 11 DESCRIPTION and 3 DOSAGE FORMS AND STRENGTHS (soft gelatin capsules for oral use).
Unsupported Statements
Vascepa slows the growth of plaque in the arteries.
Not substantiated by the provided excerpts; label text provided only describes EPA-related changes in plaque specimens and ratios, not slowing plaque growth.
Vascepa is typically taken once daily.
No dosage frequency (e.g., once daily) is present in the provided label excerpts.
Amarin Pharmaceuticals offers a discount program for eligible patients that provides discounts on Vascepa and other Amarin medications.
No discount program information appears in the provided label excerpts.
Patient assistance programs (PAPs) can help eligible patients access medications at a reduced cost.
No PAP information appears in the provided label excerpts.
Some discount cards offer discounts on Vascepa and other medications.
No discount card information appears in the provided label excerpts.
Online coupons and promo codes can be available for Vascepa and other medications.
No coupon/promo code information appears in the provided label excerpts.
Discounts and coupons may not be accepted by insurance companies.
No statements about insurance acceptance of discounts/coupons appear in the provided label excerpts.
Patients may need to pay out-of-pocket for Vascepa if discounts or coupons are not accepted by insurance.
No out-of-pocket cost or insurance-acceptance language appears in the provided label excerpts.
Patient assistance programs and manufacturer's discount programs may have eligibility requirements such as income limits or medical necessity criteria.
No eligibility-criteria language for PAPs/discount programs appears in the provided label excerpts.
Some discounts and coupons have limited quantities available.
No discount/coupon quantity limitation language appears in the provided label excerpts.
Patients may need to wait for additional quantities to become available.
No such language appears in the provided label excerpts.
Coupons and discounts may have expiration dates.
No expiration-date information appears in the provided label excerpts.
Patients may need to use coupons and discounts within a certain timeframe.
No coupon/discount time-limit language appears in the provided label excerpts.
Most discounts and coupons are only available for the patient who is taking the medication.
No discount/coupon eligibility tied to the patient appears in the provided label excerpts.
Some patient assistance programs may offer discounts or coupons for Vascepa.
No patient assistance/discount-coupon program information appears in the provided label excerpts.
Contradictions
Important Omissions
Dose frequency and full dosage/administration details (needed to verify claims like 'once daily').
Importance:
Moderate
Safety-label elements not present in provided excerpts (contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, and monitoring).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The only administration-related claim ('once daily') is not supported by the provided label excerpts, and safety-critical label sections are not provided, so adherence to contraindications/boxed warnings/monitoring cannot be verified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Many claims are unsupported by the provided label excerpts, including administration frequency and all discount/PAP program statements; additionally, safety-critical sections are missing from the excerpt set.
Suggested Improvement
Limit statements to what is explicitly supported by the provided label excerpts (e.g., omega-3/EPA description, capsule formulation, TG-lowering indications). Remove or qualify unsupported marketing/access claims and avoid stating dosage frequency unless directly supported by label dosing/administration text.